Trofentyl OTFC is an Oral transmucosal fentanyl citrate (OTFC) 200 mcg. Trofentyl OTFC is a new opioid formulation that incorporates fentanyl into a lozenge and allows drug delivery through the buccal mucosa. This kind of absorption avoids first-pass metabolism, yielding a bioavailability substantially greater than oral administration.

Trofentyl OTFC has a rapid onset of action & a short duration of effect. These characteristics, which resemble the course of a typical breakthrough pain episode, resulted in making OTFC the first opioid analgesic formulation specifically developed & approved for control of breakthrough pain in cancer patients.

Administration of Trofentyl OTFC: The patient should place the OTFC in the mouth between the cheek and lower gum, occasionally moving the drug from one side to the other using the handle. The Trofentyl OTFC unit should be sucked, not chewed. A unit dose of Trofentyl OTFC, if chewed and swallowed, might result in lower peak concentrations and lower bioavailability than when consumed as directed.

The Trofentyl OTFC unit should be consumed over a 15-minute period. Longer or shorter consumption times may produce fewer efficacies.

Indication: Trofentyl OTFC is indicated only for the breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their persistent cancer pain.

Composition: Oral Transmucosal fentanyl citrate 200 mcg.

Features:

• OTFC Lollipop (Lozenges - Tablet on a stick)
• Rapid onset of action
• Shorter duration of effect
• Pharmacokinetics does not change with multiple dosing
• Safe for long-term use at home
• Effective alternative to IV opioids
• Self controlled dosing

Presentation: 1 tablet on a stick.